RSS Feed
- 0. Dyne Therapeutics July 13, 2026Dyne Therapeutics shared positive topline results from its Phase 1/2 trial of the investigational drug, zeleciment rostudirsen (also known as DYNE-251), in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The study met its primary endpoint, demonstrating a statistically significant increase in dystrophin from baseline at 6 months. Furthermore, the treatment maintained a […]
- 1. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance July 13, 2026Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
- Fraud, waste, and abuse — a value-based care risk hiding from healthcare leaders July 13, 2026Healthcare leaders have long viewed fraud, waste, and abuse as compliance issues. But as more provider organizations accept financial risk through accountable care and other value-based arrangements, fraud, waste, and abuse are no longer simply compliance concerns.
- 00. PAPZIMEOS was granted full approval July 13, 2026PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. Effective April 1, 2026, a new, permanent HCPCS Level II J-code (J3404 - injection, zopapogene imadenovec-drba suspension, per therapeutic dose) will be available for the […]
- 6. NAMCP VBCC July 13, 2026NAMCP understands the changing landscape with regard to the delivery of healthcare moving from the traditional fee for service model to more of a focus on value based care and all of the complexities therein. The mission of the VBCC is to help payers and medical directors in their efforts to more effectively and efficiently […]
- 8. LivaNova July 13, 2026LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
- The top 10 misleading claims about antidepressants July 13, 2026Psychiatrists debunk 10 common antidepressant myths — placebo claims, addiction fears, suicide risk, overuse, and withdrawal — offering evidence-based guidance.
- 4. Gilead Sciences, Inc. July 13, 2026Gilead Sciences, Inc., a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced that the US Food and Drug Administration (FDA) has approved YEZTUGO® (lenacapavir) injection, 463.5 mg/1.5 mL. Click here for full Prescribing Information, including BOXED WARNING. Click here to learn more at YeztugoHCP.com.
- 'Seeing the evolution': As branded patent cliff looms, biosimilar experts size up US hurdles, opportunities ahead July 13, 2026The tables have turned for the U.S. biosimilars market. With more than a decade passed since the first FDA biosim approval, strong launches of biologic copies to AbbVie's Humira, J&J's Stelara and Regeneron/Bayer's Eylea are shifting a narrative once focused on lagging uptake of the category in the States.
- All of Us of Research Program hits major milestone for precision medicine July 13, 2026The National Institutes of Health recently announced another landmark in the years-long All of Us Research Program: The most expansive data release in the project's history. Data from more than 747,000 participants is now available to researchers, representing the world's largest integrated genomic and electronic health record database.
